182 related articles for article (PubMed ID: 29469177)
1. Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.
Najjar E; Stålhberg M; Hage C; Ottenblad E; Manouras A; Haugen Löfman I; Lund LH
ESC Heart Fail; 2018 Jun; 5(3):302-308. PubMed ID: 29469177
[TBL] [Abstract][Full Text] [Related]
2. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.
Pölzl G; Allipour Birgani S; Comín-Colet J; Delgado JF; Fedele F; García-Gonzáles MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Vrtovec B; Wikström G; Altenberger J
ESC Heart Fail; 2019 Feb; 6(1):174-181. PubMed ID: 30378288
[TBL] [Abstract][Full Text] [Related]
3. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
Parissis JT; Adamopoulos S; Farmakis D; Filippatos G; Paraskevaidis I; Panou F; Iliodromitis E; Kremastinos DT
Heart; 2006 Dec; 92(12):1768-72. PubMed ID: 17105880
[TBL] [Abstract][Full Text] [Related]
4. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
Comín-Colet J; Manito N; Segovia-Cubero J; Delgado J; García Pinilla JM; Almenar L; Crespo-Leiro MG; Sionis A; Blasco T; Pascual-Figal D; Gonzalez-Vilchez F; Lambert-Rodríguez JL; Grau M; Bruguera J;
Eur J Heart Fail; 2018 Jul; 20(7):1128-1136. PubMed ID: 29405611
[TBL] [Abstract][Full Text] [Related]
6. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
[TBL] [Abstract][Full Text] [Related]
7. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
[TBL] [Abstract][Full Text] [Related]
8. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
[TBL] [Abstract][Full Text] [Related]
10. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
Ponschab M; Hochmair N; Ghazwinian N; Mueller T; Plöchl W
Eur J Anaesthesiol; 2008 Aug; 25(8):627-33. PubMed ID: 18405408
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic Effects of Levosimendan in Outpatients With Advanced Heart Failure: An Echocardiographic Pilot Study.
Masarone D; Melillo E; Errigo V; Martucci ML; Pacileo R; Pollesello P; Petraio A; Pacileo G
J Cardiovasc Pharmacol; 2022 Jan; 79(1):e36-e40. PubMed ID: 34711750
[TBL] [Abstract][Full Text] [Related]
12. Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients.
Feola M; Lombardo E; Taglieri C; Vallauri P; Piccolo S; Valle R
Med Sci Monit; 2011 Feb; 17(3):PI7-13. PubMed ID: 21358614
[TBL] [Abstract][Full Text] [Related]
13. Effects of levosimendan on heart failure in normotensive patients: does loading dose matter?
Palmerini E; Söderberg S; Mondillo S; Favilli R; Lunghetti S
Acute Card Care; 2015 Mar; 17(1):14-9. PubMed ID: 25806830
[TBL] [Abstract][Full Text] [Related]
14. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
Kurt IH; Yavuzer K; Batur MK
Heart Vessels; 2010 Sep; 25(5):392-9. PubMed ID: 20676961
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of levosimendan in patients with cardiac amyloidosis.
Aimo A; Arzilli C; Castiglione V; Morfino P; Panichella G; Passino C; Vergaro G; Emdin M
Int J Cardiol; 2024 Jun; 405():131963. PubMed ID: 38479497
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
[TBL] [Abstract][Full Text] [Related]
17. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
[TBL] [Abstract][Full Text] [Related]
18. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
20. Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure.
Lelonek M; Stopczyńska I; Korościk E; Straburzyńska-Migaj E; Gruchała M
Adv Clin Exp Med; 2020 Nov; 29(11):1305-1312. PubMed ID: 33269816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
